S.L. 458.35 Art. 50Detailed explanation of scientific grounds.

Where this opinion of the Agency’s Committee for

Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.